News
Adding Ipilimumab to Nivolumab No Better in Pretreated Squamous NSCLC
No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease
Your search for non small cell lung cancer returned 472 results
News
Proteasome Inhibition May Increase Alectinib Efficacy in ALK/TP53-Mutated NSCLC
Investigators studied genetic alterations related to ALK-TKI resistance in NSCLC and explored strategies to overcome resistance in preclinical models.
News
Sotorasib Under Review for KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC
The Food and Drug Administration has placed sotorasib under priority review for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
News
Libtayo Plus Chemotherapy Approved as First-Line Treatment for Advanced NSCLC
Findings showed that treatment with cemiplimab-rwlc plus platinum-based chemotherapy demonstrated a statistically significant improvement in overall survival.
ESMO 2021, News
Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer
Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.
News
FDA Panel Rejects Lilly Cancer Drug Tested Only in China
Drug was to be used alongside chemotherapy for patients with metastatic non-small cell lung cancer
News
Erlotinib Overdose May Lead to Rapid Onset of Ocular Toxicity
Findings in case study of man being treated for non-small-cell lung cancer
News
Adding Bevacizumab May Improve Overall Survival in NSCLC
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non-small cell lung cancer
News
Tecentriq Approved for Non-Small Cell Lung Cancer
Genentech announced that the Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities.
